FDA & FTC Issue COVID-19 Claim Letters to CBD Companies - The National Law Review Article

Article – FDA & FTC Issue Warning Letters about COVID-19 Claims to CBD Companies

The U.S. Food & Drug Administration (FDA) and Federal Trade Commission (FTC) continue their crack down on COVID-19 related product claims. These two regulatory bodies have now jointly issued warning letters regarding such claims to multiple CBD companies. According to the article from The National Law Review:

“On March 28, 2022, the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) jointly issued seven warning letters to companies marketing cannabidiol (CBD) products with COVID-19 related claims.

Specifically, the agencies warned the following companies regarding the promotion of their respective products with claims that they cure, mitigate, treat or prevent COVID-19: CureganicsHeaven’s Organics LLCFunctional Remedies, LLC D/B/A Synchronicity Hemp OilGreenway Herbal Products LLCCBD SocialUPSY LLC, and Nature’s Highway. Examples of claims include: “Our research suggest that CBD . . . can block SARS-Cov-2 infection at early and even later stages of infection. . .”, “Studies Show CBD Compounds Prevent COVID Cells From Replicating”, and “Can CBD Help with the Fight Against COVID? Some of the worst effects of COVID are caused by inflammation, and CBD is a potent anti-inflammatory.”

Click here to finish reading the full article.

Wave - Momentum Factor Colors - Light Blue, Light Orange, Dark Blue - Footer Momentum Factor CHAT WITH US